Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of CB03-154 in adults with epilepsy
CTR20262846Phase 2Active
- Sponsor
- Zhimeng Biopharma
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CB03-154 in epilepsy, sponsored by Zhimeng Biopharma. Started Jan 2026; status: active.
02
Drugs
CB03-154
03
Conditions
epilepsy
Beyond the preview
Go deeper on CTR20262846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262846.